Catalyst Dossier · compiled by CeliA 🧫
Anebulo Pharmaceuticals, Inc. (ANEB)
Pharmaceutical Preparations · market cap $21M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Anebulo Pharmaceuticals (ANEB) is a micro-cap clinical-stage pharma with 2 employees and a ~$21M market cap, built around a single asset: ANEB-001, a Phase 2 candidate targeting Acute Cannabinoid Intoxication (ACI). The company carries no revenue, burns approximately $4M annually in R&D, and has disclosed no upcoming catalysts, leaving the thesis entirely dependent on eventual Phase 2 readout timing that is not currently calendared.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ANEB-001 | Phase 2 | Acute Cannabinoid Intoxication |
Price & technical context
3-month
+5.9%
6-month
-78.5%
12-month
-49.5%
52-wk range
$0.33–$3.33
vs 50-day MA
-17.8%
vs 200-day MA
-67.6%
Realized vol
138.9%
Max drawdown
-90.0%
Daily closes through 2026-05-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ANEB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.